[RESEARCH BLOG] · 2026-08-20

Moderna (MRNA) – Cancer‑Vaccine Breakthrough Fuels 177% Surge, LOPJLB Signals Strong **BUY** in a Recovery Regime

By Pierre Brunelle · Founder & Research Lead

Lede: Moderna’s shares closed at $174.4 on 2026‑08‑19 (Wednesday), a 177.0 % jump from the prior session’s level, after the company disclosed pivotal Phase 3 melanoma data and a joint cancer‑vaccine partnership with Merck.

News Cluster

Why Moderna stock skyrocketed today was the headline of a Why Moderna Stock Skyrocketed Today piece on Fool.com, which highlighted the dramatic 177 % intraday rally triggered by the release of positive Phase 3 data for its melanoma vaccine candidate. The article noted that the data not only met its primary endpoint of overall‑survival improvement but also positioned Moderna as a potential leader in the emerging class of mRNA‑based oncology therapies.

Benzinga’s coverage framed the Moderna‑Merck collaboration as a catalyst that could energize the broader mRNA‑ETF space. The report, Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For, explained that the two companies’ joint cancer‑vaccine platform—combining Moderna’s mRNA delivery expertise with Merck’s oncology pipeline—may unlock a “wave of cancer vaccines” and attract significant inflows into sector‑focused exchange‑traded funds.

The Wall Street Journal ran an opinion piece titled Opinion | Moderna’s Road to a Cancer Vaccine, arguing that the firm’s strategic pivot from pandemic‑era COVID‑19 products to oncology represents a “high‑risk, high‑reward” transition. The column cited the melanoma trial as the first tangible proof point that the company can translate its mRNA technology into durable anti‑tumor immunity, while also warning that regulatory timelines remain uncertain.

Reuters reported that the Moderna‑Merck breakthrough could usher in a new era of cancer vaccines, emphasizing that the partnership aims to develop multiple mRNA‑based immunotherapies across solid‑tumor indications. The article, Moderna, Merck breakthrough could usher in wave of cancer vaccines, highlighted that the joint effort is expected to leverage Merck’s extensive clinical‑development infrastructure and Moderna’s rapid‑manufacturing platform, potentially shortening the path to market for future candidates.

MarketWatch added that the cancer‑vaccine breakthrough helped lift a broad swath of biopharma stocks, noting that investors are “re‑pricing the odds” that mRNA will become a mainstream modality for both infectious‑disease prevention and cancer treatment. See Moderna’s cancer‑vaccine breakthrough drives broad biopharma stock rally for the full commentary.

Fundamentals and Valuation

Moderna’s current valuation metrics reflect a company still navigating a post‑pandemic transition. The trailing twelve‑month (TTM) price‑to‑earnings (P/E) ratio sits at ‑21.85, indicating that earnings are negative on a GAAP basis. Enterprise value to EBITDA (EV/EBITDA) is ‑24.30, another sign of operating losses relative to the firm’s capitalized market value.

Balance‑sheet ratios remain strained: the debt‑to‑equity (D/E) ratio is 19.04, while interest coverage is deeply negative at ‑132.8, underscoring the heavy financing burden that accompanies ongoing R&D spend. Return on invested capital (ROIC) is ‑23.52 %, and both return on equity (ROE) and return on assets (ROA) are ‑39.00 % and ‑28.75 %, respectively, reflecting the current earnings deficit.

Profitability margins are likewise in the red. Gross margin is ‑12.57 %, operating margin ‑149.0 %, and net margin ‑141.4 %. Free‑cash‑flow (FCF) yield is ‑1.77 %, indicating that cash generation is insufficient to cover the firm’s capital needs without external financing.

Despite the negative earnings profile, analysts maintain a target price of $94.78 and a consensus “Hold” recommendation, suggesting that the market still sees upside potential if the oncology pipeline materializes. The Altman Z‑score of 10.10 signals a low probability of bankruptcy, largely because the company retains a sizable cash balance of $7.5 B as of Q1 2026.

Valuation Snapshot

Multi‑Year Financial Trajectory

Moderna’s revenue and profitability have been highly volatile over the past six years, reflecting the boom‑bust cycle of its COVID‑19 vaccine business and the subsequent shift toward a diversified mRNA pipeline.

• 2020: Revenue of $803.4 M with a GAAP loss per share (EPS) of ‑1.96. Despite the modest top line, free cash flow (FCF) was $1.96 B, driven by government contracts for Spikevax. Gross margin was a healthy 95.12 %, but operating and net margins were deeply negative (‑94.99 % and ‑92.99 %, respectively).

• 2021: A dramatic surge to $17.74 B in revenue as the COVID‑19 vaccine rollout accelerated. EPS turned positive at $30.31, and FCF exploded to $13.34 B. Margins improved dramatically, with gross margin at 85.24 %, operating margin 74.97 %, and net margin 68.80 %. ROE and ROA peaked at 86.26 % and 49.46 %, respectively, reflecting the extraordinary profitability of the pandemic response.

• 2022: Revenue continued to climb modestly to $18.88 B, while EPS fell to $21.26 as the company began to absorb higher manufacturing costs and pricing pressures. Gross margin slipped to 71.31 %, operating margin to 49.91 %, and net margin to 44.30 %. ROE and ROA remained strong at 43.73 % and 32.34 %.

• 2023: A sharp reversal as COVID‑19 demand waned. Revenue collapsed to $6.85 B, EPS turned negative (‑12.34), and FCF swung to a ‑$3.83 B outflow. Gross margin fell to 31.47 %, operating margin to ‑61.90 %, and net margin to ‑68.84 %. ROE and ROA became negative (‑34.03 % and ‑25.58 %), underscoring the earnings headwinds.

• 2024: Revenue further declined to $3.20 B, with EPS at ‑9.27 and FCF at ‑$4.06 B. Margins deteriorated further, with operating margin plunging to ‑123.3 % and net margin to ‑111.3 %. ROE and ROA stayed negative, indicating that the company was still in a restructuring phase.

• 2025: Revenue continued its downward trajectory to $1.94 B, EPS at ‑7.26, and FCF at ‑$2.07 B. Gross margin modestly recovered to 55.35 %, but operating margin remained deeply negative (‑158.1 %) and net margin ‑145.2 %. ROE and ROA persisted in negative territory (‑32.62 % and ‑22.87 %).

The historical pattern shows a classic “boom‑bust‑re‑investment” cycle: a massive pandemic‑driven revenue surge, followed by a steep decline as demand receded, and now a strategic pivot toward oncology and other mRNA therapeutics. The current $174.4 share price reflects both the market’s pricing of the recent melanoma breakthrough and the lingering uncertainty around the company’s ability to translate that success into sustainable earnings.

ETF Ownership

Moderna is held by 65 ETFs, with the top twelve accounting for roughly 55 % of the total ETF exposure. Concentrated ownership by sector‑focused funds can amplify price moves when the underlying theme (in this case, mRNA‑based therapeutics) experiences a catalyst.

The presence of these ETFs—many of which specialize in biotech, gene‑therapy, or broader healthcare themes—means that a single positive data readout can trigger coordinated buying across multiple fund managers, reinforcing the price rally observed on August 19.

Earnings Call

The most recent earnings narrative, spanning eight quarters, paints a picture of a company balancing cost discipline with pipeline progress while wrestling with demand uncertainty.

• Cross‑quarter tone: Management’s commentary has shifted from early‑2024 concerns over weak EU demand and US competitive pressure to a more optimistic stance that highlights cost cuts and regulatory approvals.

• 2026 Q1 one‑liner:

“Moderna Q1 2026: $400 M revenue (+$300 M YoY), net loss $1.3 B GAAP ($0.5 B ex‑litigation), cash $7.5 B; reiterated up to 10 % FY revenue growth; EU approvals for mNEXSPIKE and flu+COVID combo; flu PDUFA Aug 5; Intismeran Phase III in Stage 1 NSCLC monotherapy initiated; norovirus Phase III enrolled; $950”

• Guidance: The company provided vague guidance for FY 2026, indicating that revenue growth will be “up to 10 %” but stopping short of a precise range. This reflects lingering uncertainty around flu‑vaccine market entry and the timing of additional oncology readouts.

• Theme arcs:

  • Cost discipline (improving) – Management repeatedly cited $400 M in accelerated cost reductions, including a 10 % headcount cut and $400 M in expense curtailments.
  • Regulatory approvals (improving) – Recent EU approvals for mNEXSPIKE and a flu‑COVID combination vaccine signal a diversification beyond COVID‑19.
  • Pipeline progress (stable) – Initiation of Phase III for Intismeran in non‑small‑cell lung cancer (NSCLC) and enrollment in a norovirus Phase III trial demonstrate continued R&D momentum.
  • Demand uncertainty (deteriorating) – Declining COVID‑19 vaccine uptake and competitive pressures in the flu market remain prominent risk factors.
  • Partnerships (new) – The Merck collaboration expands Moderna’s oncology footprint and may open additional co‑development pathways.

• Risks: The call highlighted demand risk (waning COVID‑19 vaccine sales), regulatory risk (pending flu and combo vaccine approvals), clinical risk (mixed outcomes in CMV and norovirus programs), and a new market risk from established flu‑vaccine competitors.

Overall, the earnings discussion underscores a company that has stabilized its cost base, secured key regulatory milestones, and leveraged strategic partnerships, yet still faces a volatile revenue outlook as it transitions away from pandemic‑driven cash flows.

LOPJLB Signal Overview

• Directional Signal: BUY
• Market Regime: RECOVERY (the broader market has been in a bullish stance for the past four days, with a 61 % long‑breadth signal driven by an EMA bullish crossover).
• Composite Scores: PERF = 63.10, FUND = 0.00
• Factor Tilt: Value = 0.00, Growth = 3.00, GARP = 7.80, Quality = 31.00
• Archetype: Balanced

The LOPJLB model flags Moderna as a balanced‑type stock, meaning it exhibits a mix of growth potential (driven by the oncology pipeline) and quality considerations (moderate quality score, strong cash position). The BUY direction, combined with a RECOVERY market regime, suggests that the model expects the recent catalyst to translate into further upside as the broader market sentiment remains supportive.

Readers can explore the interactive price chart above, which overlays the LOPJLB technical signals, and dive deeper into the methodology that powers these scores on the LOPJLB methodology page.

Where to Go Next

• Detailed stock profile and real‑time data: https://www.lopjlb.com/stock/MRNA
• Full earnings‑call transcript and analysis: https://www.lopjlb.com/stock/MRNA/earnings.md
• Screen for similar biotech opportunities: https://www.lopjlb.com/screener

All content presented is for informational research purposes only and does not constitute investment advice. Readers should conduct their own due diligence and consult professional advisors before making any investment decisions.

This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.

Open MRNA signal detail → · Open screener → · Methodology